ELMOX 250

Main information

  • Trade name:
  • ELMOX 250 10 CAP
  • Pharmaceutical form:
  • CAP
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ELMOX 250 10 CAP
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

1-3-2018

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

FDA - U.S. Food and Drug Administration

18-1-2018

Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

Use of a non-sterile injectable product could result in fatal infections.

FDA - U.S. Food and Drug Administration

18-1-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Levofloxacin in 5% Dextrose 250mg/50mL Due to Presence of Visible Particulate Matter Tentatively Identified as Mold

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Levofloxacin in 5% Dextrose 250mg/50mL Due to Presence of Visible Particulate Matter Tentatively Identified as Mold

FOR IMMEDIATE RELEASE – 01-12-2018 – East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level. The product has been found to contain visible particulate matter tentatively identified as mold. This problem was discovered as a result of a product complaint in which the contents of one flexible bag was found to contain whi...

FDA - U.S. Food and Drug Administration

31-1-2018

Scientific guideline:  Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

30-1-2018

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

Updated Date: Jan 30, 2018 EST

US - DailyMed

17-1-2018

Mvasi (Amgen Europe B.V.)

Mvasi (Amgen Europe B.V.)

Mvasi (Active substance: bevacizumab) - Centralised - Authorisation - Commission Decision (2018)250 of Wed, 17 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4728

Europe -DG Health and Food Safety

29-12-2017

METRONIDAZOLE 250 MG (Metronidazole) Tablet, Film Coated [Vivimed Labs Limited]

METRONIDAZOLE 250 MG (Metronidazole) Tablet, Film Coated [Vivimed Labs Limited]

Updated Date: Dec 29, 2017 EST

US - DailyMed

29-12-2017

K-BROVET 250 (Potassium Bromide) Tablet, Chewable [Pegasus Laboratories, Inc.]

K-BROVET 250 (Potassium Bromide) Tablet, Chewable [Pegasus Laboratories, Inc.]

Updated Date: Dec 29, 2017 EST

US - DailyMed